Company intelligence / Profile preview

Aerin Medical

Mountain View, California, United States

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

VivAer® and RhinAer® are FDA-cleared, office-based devices for treating nasal airway obstruction and chronic rhinitis. Multiple studies—including three-year follow-up RCTs—demonstrate durable safety and effectiveness of temperature-controlled radiofrequency ablation for these conditions. Over 150,000 patients have been treated with these technologies to date.

Therapeutic areas: PulmonologyImmunology
Modalities: DeviceNon-pharmacological therapyRadiofrequency-based therapy (temperature-controlled radiofrequency)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

VivAer

Commercial

Indications: Nasal airway obstruction

1 more asset in the full pipeline.

Request access →

Partnerships

None specifically disclosed with major pharma or biotech companies as of June 2025.

Beyond the preview

Go deeper on Aerin Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aerin Medical.

Explore the full profile